The pandemic has accelerated the use and implementation of digital technologies globally. So much so that in a survey performed by Verdict, 35% of respondents out of 482 polled, opined that the pandemic has accelerated digital transformation in the pharmaceutical industry by five years.

When working to stay up-to-date on the latest technological trends, pharmaceutical business teams must determine which tech tools are here to stay and which are simply fads. In the pharma industry, the use of artificial intelligence (AI) and predictive analytics has skyrocketed in recent years, touching every aspect of the market, from drug discovery to business operations. Predictive analytics technologies have become valuable tools for pharma companies because they allow teams to better understand their customers and make more informed decisions when evaluating what comes next in their market. Because of these powerful applications, AI and predictive analytics are here to stay for the future of pharma.

As part of the NEXT Normal Pharma Summit of 2022, it was my pleasure to sit down with Francesca Wuttke (former Chief Digital Officer of Almirall, and most recently the Founder and CEO of nen, as well as John Lineen, the Senior Director of Engagement Planning, Immunology and Cardiovascular Franchises at BMS, to discuss the state of pharma’s investments in digital tools, talent and partnerships. Here are some key takeaways from this great session.